Cargando…

Homologous Recombination Repair in Biliary Tract Cancers: A Prime Target for PARP Inhibition?

SIMPLE SUMMARY: Biliary tract cancers (BTCs) are a rare but deadly group of gastrointestinal tumors that are often diagnosed in the advanced stages of disease. Despite large studies investigating optimal systemic therapy options in BTCs, current chemotherapies provide only modest benefits in overall...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Chao, Kulasekaran, Monika, Roy, Tina, Decker, Brennan, Alexander, Sonja, Margolis, Mathew, Jha, Reena C., Kupfer, Gary M., He, Aiwu R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140037/ https://www.ncbi.nlm.nih.gov/pubmed/35626165 http://dx.doi.org/10.3390/cancers14102561

Ejemplares similares

PARP1 suppresses homologous recombination events in mice in vivo
por: Claybon, Alison, et al.
Publicado: (2010)

PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations
por: von Werdt, Alexander, et al.
Publicado: (2021)

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
por: Ricci, Angela Dalia, et al.
Publicado: (2020)

Methylated-UHRF1 and PARP1 interaction is critical for homologous recombination
por: Hahm, Ja Young, et al.
Publicado: (2020)

WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors
por: Burdova, Kamila, et al.
Publicado: (2019)

Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer
por: Seo, Hye-Rim, et al.
Publicado: (2022)

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
por: Keung, Man Yee T., et al.
Publicado: (2019)

Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers
por: Janysek, Dawn C., et al.
Publicado: (2021)

Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors
por: Xu, Junfen, et al.
Publicado: (2021)

PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components
por: O’Sullivan Coyne, Geraldine, et al.
Publicado: (2022)

PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA
por: Sugimura, Kazuto, et al.
Publicado: (2008)

PARP3 affects the relative contribution of homologous recombination and nonhomologous end-joining pathways
por: Beck, Carole, et al.
Publicado: (2014)

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors
por: Lahiguera, Álvaro, et al.
Publicado: (2020)

BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair
por: Zhang, Shaolu, et al.
Publicado: (2021)

Loss of CENP-I Impairs Homologous Recombination and Sensitizes Cells to PARP1 Inhibition
por: Dang, Tuyen T., et al.
Publicado: (2021)

The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells
por: De Lorenzo, Silvana B., et al.
Publicado: (2013)

Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality
por: Sanese, Paola, et al.
Publicado: (2020)

Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents
por: Póti, Ádám, et al.
Publicado: (2019)

ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells
por: Verma, Priyanka, et al.
Publicado: (2021)

Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors
por: Miller, Rowan E, et al.
Publicado: (2022)

Targeting MALAT1 Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate Cancer
por: Yadav, Anjali, et al.
Publicado: (2023)

The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors
por: Peng, Yihan, et al.
Publicado: (2019)

Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma
por: Ning, Jian-Fang, et al.
Publicado: (2019)

Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors
por: Wang, Junhui, et al.
Publicado: (2015)

Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells
por: Schoonen, Pepijn M., et al.
Publicado: (2017)

SPDR-01 INHIBITION OF HOMOLOGOUS RECOMBINATION, PARP INHIBITOR, OR DIANHYDROGALACTITOL OVERCOMES TEMOZOLOMIDE-RESISTANCE IN GLIOMA CELLS
por: Ohba, Shigeo, et al.
Publicado: (2019)

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
por: Chopra, Neha, et al.
Publicado: (2020)

VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases
por: Ekstrom, Thomas L., et al.
Publicado: (2021)

Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors
por: Amin, Oreekha, et al.
Publicado: (2015)

Redundancy between nucleases required for homologous recombination promotes PARP inhibitor resistance in the eukaryotic model organism Dictyostelium
por: Kolb, Anna-Lena, et al.
Publicado: (2017)

Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition
por: Pai Bellare, Ganesh, et al.
Publicado: (2021)

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer
por: Dillon, Kasia M., et al.
Publicado: (2022)

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
por: Lu, Xue, et al.
Publicado: (2022)

ATR Inhibitor Synergizes PARP Inhibitor Cytotoxicity in Homologous Recombination Repair Deficiency TK6 Cell Lines
por: Wikiniyadhanee, Rakkreat, et al.
Publicado: (2023)

SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair
por: Lin, Shengbin, et al.
Publicado: (2022)

Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival
por: Xie, Tao, et al.
Publicado: (2022)

PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma
por: Majuelos-Melguizo, Jara, et al.
Publicado: (2014)

Loss of NFBD1/MDC1 disrupts homologous recombination repair and sensitizes nasopharyngeal carcinoma cells to PARP inhibitors
por: Wang, Zhihai, et al.
Publicado: (2019)

BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance
por: Nacson, Joseph, et al.
Publicado: (2018)

Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors
por: Criscuolo, Daniela, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2v89k75oc90dei9o6oc5kvrtmc